Eli Lilly (LLY)
(Delayed Data from NYSE)
$757.70 USD
-2.30 (-0.30%)
Updated May 13, 2024 04:00 PM ET
After-Market: $757.10 -0.60 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
LLY 757.70 -2.30(-0.30%)
Will LLY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LLY
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
Zacks Investment Ideas feature highlights: Eaton, Eli Lilly and Arista Networks
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Stocks to Buy Following Guidance Upgrades
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Other News for LLY
BoA raises 2024 Novo Nordisk Wegovy sales estimates on prescription trends
Ex-Dividend Reminder: Eli Lilly, Select Medical Holdings and LeMaitre Vascular
The Must-Watch List: 3 Stocks to Snap Up as Soon as They Hit Bargain Territory
Healthcare And Biotech Investing 101: What You Need To Know.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), TruBridge (TBRG) and Ligand Pharma (LGND)